Strides receives FDA green light for triamcinolone acetonide

Patients seeking relief of certain types of skin conditions will soon have a new generic treatment available.

The Food and Drug Administration has cleared Strides Pharma’s triamcinolone acetonide ointment in a dosage strength of 0.05%.The product is indicated for inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Triamcinolone acetonide ointment, 0.05% had a market value of approximately $15 million, according to IQVIA.

The product will be manufactured at the company’s flagship facility at Bangalore.